|
|
|
| home > ebr > Spring 2018 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
Editor’s Letter
EBR Editor Dr Deborah O’Neil looks at the potential of cannabis use in healthcare, relating it to topics discussed in this edition.
|
|
|
|
Future Migraine Treatment
Getting Ahead
Recent advancements in biopharmaceuticals in the area of migraine studies have the potential to bring relief to many individuals. Professor Dr Uwe Reuter at Charité Universitätsmedizin explains how.
|
|
|
|
|
Immunogenicity and the Development of Biopharmaceuticals
Sudden Impact
Dr Gary Bembridge and Dr Karen Hills at Abzena comment on the approaches that can be taken in the pre-clinical stages to reduce the effects of immunogenicity on patient experience and product success.
|
|
|
Technologies for Targeting the Cell Surfaceome
Scratching the Surface
Dr Maria Pavlou and Dr Paul Helbling at Dualsystems Biotech suggest that developing methodologies to study the surfaceome is crucial to cellular differentiation advancement, resulting in the creation of new treatments.
|
|
|
The Potential of Bacterial Lysates
From Pharma to Beauty
Bacterial lysates can be used in many applications, especially disease protection, due to their ability to act as an immune stimulant. Dr Christian Sanchez and Maxence de Villemeur at Lallemand Pharma analyse further.
|
|
|
|
Regulatory Challenges
Rules for Success
Dr William Bridges at Regulatory Affairs Professionals Society believes that regulatory aspects can propel an organisation towards success by enforcing policies, compliance, and good practices.
|
|
|
|
In Brief
Precision Healthcare
EBR’s Industry Advisor, Emile Bellott, surveys the potential ramifications of Amazon’s recently announced healthcare services, which aims to be an affordable solution for consumers.
|
|
|
|
Q&A: Albumin in Cell Culture
Therapy at Work
EBR asked Dr Daniel Shelly at Albumedix about cell therapy, looking specifically at the use of albumin in cell culture and current treatments, as well as the challenges that have to be overcome.
|
|
|
Animal Component-Free Media Formulations
Blood-Free Matters
Dr Randall Alfano at InVitria Product Development describes the use of fetal bovine serum in the advancement of in vitro biology, but suggests that a serum-free media formulation could enhance safety and reproducibility.
|
|
|
Customised Viral Engineering
Proactive Progress
Customised viral engineering can create safe and effective adeno-associated virus gene delivery, reveal Tatjana Buchholz at PlasmidFactory, Dr Carl J Christel at Sirion Biotech, and Dr Hüseyin Besir at PROGEN Biotechnik.
|
|
|
|
|
Capturing Protein-Defining Information
Redefining Proteomics
Mass spectrometry can find the proteins that make a sample, but Dr Christian Loch at AVMBioMed highlights the extract-based functional assay technique.
|
|
|
|
|
Personalised Medicine
At a Glance
Is society ready for personalised medicines and its ethical implications? Guenther Proll at Biametrics has the answer and examines the progress of its sequencing.
|
|
|
Precision Medicine
Beyond the Genome
Dr Jason Mellad at Cambridge Epigenetix states that collaboration is key to realising the potential of epigenetic research, and successive innovations and applications can aid the industry’s understanding of this.
|
|
|
Biomarkers in Oncology
Tomorrow’s Treatments
Tarquin Edwards at Peckwater PR claims that personalising cancer care and using biomarkers and personalised medicine in oncology is being supported by Big Pharma, thus transforming cancer treatments.
|
|
|
|
|
Biobanks and Strategic Processes
Data Swap
Colin Thurston at Brooks Life Sciences recommends adopting three key biobank technology solutions to make research more stratified and effective, thereby aiding researchers.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Sanner consistently invests in own tool and mold making
Bensheim, Germany, February 3, 2021 – Sanner, manufacturer
of pharmaceutical primary packaging and medical technology products, is
investing in the expansion of its in-house tool and mold making. This
enables the company to ensure rapid delivery of standard products that
are in high demand especially in times of pandemic, such as desiccant
closures and nutritional supplements packaging. However, the investments
are also paying off in the development and implementation of new
products and will be consistently continued in 2021.
More info >> |
|
 |
White Papers |
 |
|
ECCRT
ECCRT
The European Centre for Clinical Research Training (ECCRT) is a professional clinical research training provider focusing on the transfer of implementable knowledge for the day-to-day activities of our participants whether being new to the industry, starters on the job, or seasoned professionals. Our mission is to facilitate Clinical Research professionals to excel in their job for the benefit of patients. We aim to achieve this by providing clinical research professionals with competencies to develop new therapies for patients quicker & more efficiently, without jeopardizing quality and safety.
More info >> |
|
 |
Industry Events |
 |
Bio Integrates 2021
20 May 2021, VIRTUAL CONFERENCE
Following the continued success of last year’s inaugural digital event,
Life Science Integrates is delighted to announce the 3rd Bio Integrates
conference. Addressing the needs of innovative companies developing the
therapies of tomorrow, this one-day conference provides a unique forum
to discuss the major challenges impacting the sector.
More info >> |
|
|
.jpg)
